Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorAlsina Maqueda, Maria
dc.contributor.authorDiez Garcia, Marc
dc.contributor.authorTabernero Caturla, Josep
dc.date.accessioned2022-08-11T11:56:02Z
dc.date.available2022-08-11T11:56:02Z
dc.date.issued2022-03-10
dc.identifier.citationAlsina M, Tabernero J, Diez M. Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond. Cancers. 2022 Mar 10;14(6):1408.
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/11351/7992
dc.descriptionGastric cancer; Molecular approach; Third line of treatment
dc.description.abstractGastric and gastro-oesophageal junction cancer (GC) represent a global healthcare problem being the fifth most common tumour type and the fourth cause of cancer mortality. Extremely poor median survival of approximately 10 months is normally reported within advanced GC patients, mainly secondary to two factors, i.e., the fragility of these patients and the aggressiveness of this disease. In this context, the correct treatment of GC patients requires not only a multidisciplinary team with special attention to palliative and nutritional care but also a close follow-up with regular monitoring of disease symptoms and tumour evaluation. Sequential treatment lines with few toxic adverse events have emerged as the best therapeutic approach, and a third line of therapy could further improve survival and quality of life of GC patients. Chemotherapy, immunotherapy, and targeted agents -when indicated- constitute the treatment armamentarium of these patients. In this review, we discuss treatment options in the refractory setting as well as novel approaches to overcome the poor prognosis of GC.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesCancers;14(6)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectEstómac - Càncer - Tractament
dc.subjectMedicaments antineoplàstics - Efectes secundaris
dc.subject.meshStomach Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshAntineoplastic Agents
dc.subject.mesh/adverse effects
dc.titleChemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/cancers14061408
dc.subject.decsneoplasias gástricas
dc.subject.decs/farmacoterapia
dc.subject.decsantineoplásicos
dc.subject.decs/efectos adversos
dc.relation.publishversionhttps://doi.org/10.3390/cancers14061408
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Alsina M] Gastrointestinal & Endocrine Tumours Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Medical Oncology Department, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain. [Tabernero J, Diez M] Gastrointestinal & Endocrine Tumours Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid35326560
dc.identifier.wos000775920300001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record